Alexion PharmaceuticalsのIPO年
Alexion PharmaceuticalsのIPO年は何ですか。
Alexion Pharmaceuticals Inc.のIPO年は1996です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
NASDAQのセクタHealth CareにおけるIPO年の企業と比べるAlexion Pharmaceuticals
Alexion Pharmaceuticalsは何をしますか。
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticalsと類似のipo年
- Shaw CommunicationsのIPO年は1995です。
- HuskyのIPO年は1995です。
- Transcontinental , Cl B MvのIPO年は1995です。
- Mountain IncのIPO年は1995です。
- Brookfield Asset ManagementのIPO年は1995です。
- ShawCorのIPO年は1995です。
- Alexion PharmaceuticalsのIPO年は1996です。
- BXPのIPO年は1997です。
- Faro TechnologiesのIPO年は1997です。
- SilganのIPO年は1997です。
- Warrior GoldのIPO年は1997です。
- Ryanair PlcのIPO年は1997です。
- SIGA Technologies IncのIPO年は1997です。